Related Experiment Videos
Combating Gram-positive pathogens: emerging techniques to identify relevant virulence targets.
J E Shea1, J D Santangelo, R G Feldman
1Microscience Ltd., 545 Eskdale Road, Winnersh Triangle, Wokingham, Berkshire, RG41 5TU, UK. j.shea@microscience.com
Expert Opinion on Therapeutic Targets
|July 5, 2005
Summary
Functional genomics technologies like in vivo expression technology (IVET) and signature-tagged mutagenesis (STM) are crucial for identifying Gram-positive virulence genes. These genes are promising targets for developing new antimicrobial drugs.
Area of Science:
- Microbiology
- Genomics
- Drug Discovery
Background:
- Advances in microbial genome sequencing and functional genomics have enabled the identification of numerous virulence genes in Gram-positive bacteria.
- These virulence genes represent a diverse set of potential targets for novel antimicrobial therapies.
Purpose of the Study:
- To review the contribution of two key functional genomics technologies to the identification of virulence genes in Gram-positive pathogens.
- Focus on in vivo expression technology (IVET) and signature-tagged mutagenesis (STM).
Main Methods:
- In vivo expression technology (IVET) for monitoring gene expression within a host.
- Signature-tagged mutagenesis (STM) for genetic screening of virulence factors.
Main Results:
- Both IVET and STM have proven effective in identifying significant numbers of Gram-positive virulence genes.
- These technologies facilitate a deeper understanding of pathogen-host interactions.
Conclusions:
- Functional genomics approaches, particularly IVET and STM, are vital for discovering novel antimicrobial drug targets.
- Targeting Gram-positive virulence genes holds significant promise for combating bacterial infections.